FMP
NASDAQ
2.07 USD
0.0308 (1.49%)
Mr. James F. Oliviero III, C.F.A.
Healthcare
Biotechnology
https://www.checkpointtx.com
NASDAQ
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a tre...
0001651407
US1628282063
162828107
95 Sawyer Road
781 652 4500
US
23
Dec 19, 2016
0001651407
NASDAQ
Biotechnology
Healthcare
162828107
US1628282063
US
2.07
1
600.09k
47.27M
-
1.3-3.62
0.26
-
-
-
-
-0.65
-
https://www.checkpointtx.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.